Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cytosorbents ( (CTSO) ) has issued an announcement.
On March 25, 2026, CytoSorbents reported that revenue for the year ended December 31, 2025 rose 4% to $37.1 million, with gross margin improving to 71% and operating loss narrowing to $14.7 million. The company’s 2025 net loss shrank sharply to $8.2 million, while adjusted EBITDA loss improved to $10.5 million, reflecting cost controls and balance sheet support that included an amended credit facility.
Fourth-quarter 2025 revenue edged up 1% to $9.2 million as gross margin expanded to 74%, though operating loss widened to $4.6 million due to restructuring charges from a workforce and cost reduction program aimed at reaching cash-flow breakeven in 2026. Management highlighted a strategic shift in German sales, stronger direct and distributor sales elsewhere, milestone clinical adoption surpassing 300,000 CytoSorb treatments worldwide, and ongoing FDA discussions on a new De Novo submission for its DrugSorb-ATR device, underscoring both commercial traction and regulatory progress in critical care blood purification.
The most recent analyst rating on (CTSO) stock is a Hold with a $0.60 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.
Spark’s Take on CTSO Stock
According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.
Cytosorbents’ overall stock score is primarily impacted by its challenging financial performance, characterized by high leverage and negative cash flows. The technical analysis indicates a bearish trend, while the valuation is unattractive due to ongoing losses. The earnings call provides some optimism with strategic initiatives, but risks remain, particularly with the Nasdaq compliance issue.
To see Spark’s full report on CTSO stock, click here.
More about Cytosorbents
CytoSorbents Corporation, based in Princeton, N.J., is a medical technology company focused on treating life-threatening conditions in intensive care and cardiac surgery through blood purification therapies. Its flagship CytoSorb device and related hemoadsorption technologies are used globally, with growing adoption across more than 70 countries, particularly in sepsis, septic shock, acute liver failure and cardiogenic shock.
Average Trading Volume: 85,592
Technical Sentiment Signal: Sell
Current Market Cap: $43.7M
For a thorough assessment of CTSO stock, go to TipRanks’ Stock Analysis page.